短乳杆菌SLlac-18安全性评价及对高尿酸血症小鼠的益生作用OA

Hyperuricaemia is a metabolic disease characterized by uric acid metabolism disorder.Probiotics have the characteristics of being economical and effective with few toxic side effects and relatively high safety for alleviating hyperuricemia.In this study,we evalua-ted the safety of a previously isolated strain of Lactobacillus brevis SLlac-18 from a pickle with potential uric acid-lowering function and constructed a hyperuricemia mice model to investigate the probiotic effects of L.brevis SLlac-18 on hyperuricemic mice.The results showed that L.brevis SLlac-18 had no haemolytic activity,and there were no significant differences in body weight,organ indices,and blood rou-tine indexes in mice gavaged with strain compared to the control group,and no significant pathological changes in liver and kidney tissue were observed.Additionally,compared with the model group,the expression levels of uric acid and xanthine oxidase(XOD)in serum were decreased to 32.02％and 80.77％respectively in the SLlac-18 group(P＜0.01),liver and kidney tissue damage was improved by L.brevis SLlac-18,and the XOD activity was decreased to 63.38％(P＜0.01),the expression of uric acid reabsorption transporter pro-tein GLUT9 was reduced to 23.74％and the expression the uric acid secretion transporter protein NPT1 was increased to 23.68％.In con-clusion,L.brevis SLlac-18 exhibits a favorable safety profile and exerts beneficial effects in hyperuricemic mice through multiple pathways,holding promise for the prevention and adjuvant therapy of hyperuricemia.